Key result
Monoclonal antibodies COV2-2676 and COV2-2489 potently neutralize SARS-CoV-2 and protect mice from infection.
Why the study?
Most human monoclonal antibodies neutralizing SARS-CoV-2 target the spike protein receptor-binding domain, but the role and characteristics of antibodies targeting the N-terminal domain were less defined.
Population
Human monoclonal antibodies from SARS-CoV-2 convalescent donors
Comparison
Neutralizing NTD-specific mAbs versus non-neutralizing NTD-binding mAbs
Design
Preclinical mechanistic study with viral infection models
Authors
Loading...
NTD-neutralizing mAbs may expand therapeutic options beyond RBD; leaves open clinical translation pending further validation.
Natural infection induces a subset of potent NTD-specific mAbs that leverage neutralizing and Fc-mediated activities to protect against SARS-CoV-2 infection.
Suryadevara et al. (2021) studied SARS-CoV-2 infection. COV2-2676 and COV2-2489 vs. Isotype control mAb DENV-2D22 was evaluated on In vivo protection against SARS-CoV-2 challenge (weight loss and viral burden). COV2-2676 and COV2-2489, human monoclonal antibodies targeting the N-terminal domain of the SARS-CoV-2 spike protein, potently neutralized the virus and protected mice from infection and weight loss.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: